IS5712A - Faststilling lyfjablandna sem í eru angíótensínumbreytiensím með magnesíumoxíði - Google Patents

Faststilling lyfjablandna sem í eru angíótensínumbreytiensím með magnesíumoxíði

Info

Publication number
IS5712A
IS5712A IS5712A IS5712A IS5712A IS 5712 A IS5712 A IS 5712A IS 5712 A IS5712 A IS 5712A IS 5712 A IS5712 A IS 5712A IS 5712 A IS5712 A IS 5712A
Authority
IS
Iceland
Prior art keywords
determination
pharmaceutical compositions
magnesium oxide
compositions containing
converting enzyme
Prior art date
Application number
IS5712A
Other languages
English (en)
Other versions
IS2270B (is
Inventor
Ellen Daniel Jane
Ray Harris Michael
Original Assignee
Warner - Lambert Company, , Delaware Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22210458&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS5712(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner - Lambert Company, , Delaware Corporation filed Critical Warner - Lambert Company, , Delaware Corporation
Publication of IS5712A publication Critical patent/IS5712A/is
Publication of IS2270B publication Critical patent/IS2270B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS5712A 1998-06-05 2000-11-10 Faststilling lyfjablandna sem í eru angíótensínumbreytiensím með magnesíumoxíði IS2270B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8828098P 1998-06-05 1998-06-05
PCT/US1999/010189 WO1999062560A1 (en) 1998-06-05 1999-05-10 Stabilization of compositions containing ace inhibitors using magnesium oxide

Publications (2)

Publication Number Publication Date
IS5712A true IS5712A (is) 2000-11-10
IS2270B IS2270B (is) 2007-07-15

Family

ID=22210458

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5712A IS2270B (is) 1998-06-05 2000-11-10 Faststilling lyfjablandna sem í eru angíótensínumbreytiensím með magnesíumoxíði

Country Status (32)

Country Link
US (3) US6417196B1 (is)
EP (1) EP1083931B1 (is)
JP (1) JP3727848B2 (is)
KR (1) KR20010052557A (is)
CN (1) CN1144598C (is)
AR (1) AR019150A1 (is)
AT (1) ATE295184T1 (is)
AU (1) AU755616B2 (is)
BR (1) BR9910947A (is)
CA (1) CA2330581A1 (is)
CO (1) CO5011043A1 (is)
DE (1) DE69925269T2 (is)
ES (1) ES2242398T3 (is)
GT (1) GT199900079A (is)
HK (1) HK1038879B (is)
HN (1) HN1999000088A (is)
HU (1) HUP0102260A3 (is)
ID (1) ID27398A (is)
IL (1) IL139590A0 (is)
IS (1) IS2270B (is)
MY (1) MY119667A (is)
NO (1) NO20006148D0 (is)
NZ (1) NZ508544A (is)
PA (1) PA8475001A1 (is)
PE (1) PE20000543A1 (is)
PL (1) PL344586A1 (is)
SV (1) SV1999000072A (is)
TR (1) TR200003600T2 (is)
TW (1) TW565455B (is)
UY (1) UY25546A1 (is)
WO (1) WO1999062560A1 (is)
ZA (1) ZA200006537B (is)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69925269T2 (de) * 1998-06-05 2006-02-23 Warner-Lambert Co. Llc Stabilisierung von zusammensetzungen enthaltend ace-hemmer durch magnesiumoxid
NZ333206A (en) 1998-12-08 2000-07-28 Bernard Charles Sherman Solid pharmaceutical compositions comprising a stable magnesium salt of quinapril that acts as a ACE (Angiotensin Converting Enzyme) inhibitor
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
EP1300160B1 (en) * 2000-05-24 2014-03-12 Otsuka Pharmaceutical Co., Ltd. Method of stabilizing preparation
AU2003235579A1 (en) * 2002-01-15 2003-07-30 Delta Hf. Formulations of quinapril and related ace inhibitors
US20030157165A1 (en) * 2002-02-01 2003-08-21 Sherman Bernard Charles Stable saccharide-free tablets comprising a salt of quinapril or moexipril
US7638138B2 (en) * 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
CA2519287A1 (en) 2003-03-27 2004-10-14 Bioactis Limited Powder medicine applicator for nasal cavity
CZ298224B6 (cs) * 2003-04-29 2007-07-25 Pliva Istrazivanje I Razvoj D.O.O. Farmaceutická kompozice obsahující jako úcinnou látku ribavirin a zpusob její výroby
DK1635792T3 (da) * 2003-06-26 2009-06-15 Teva Pharma Stabile farmaceutiske sammensætninger af 2-aza-bicyklo-3.3.0-oktan-3-carboxylsyrederivater
US8673360B2 (en) * 2004-08-10 2014-03-18 Shin Nippon Biomedical Laboratories, Ltd. Compositions that enable rapid-acting and highly absorptive intranasal administration
US20060141054A1 (en) 2004-10-25 2006-06-29 Thomas Piccariello Metal coordinated compositions
US7799937B2 (en) 2004-10-25 2010-09-21 Synthonics, Inc. Metal coordinated compositions
US8779175B2 (en) 2004-10-25 2014-07-15 Synthonics, Inc. Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients
ITMI20060026A1 (it) * 2006-01-10 2007-07-11 Truffini & Regge Farmaceutici Srl Composizioni per uso rale a base di s-adenosilmetionina e processo per il loro ottenimento
EP1815857A1 (en) 2006-02-02 2007-08-08 LEK Pharmaceuticals D.D. A pharmaceutical composition comprising perindopril
US20070232680A1 (en) * 2006-04-04 2007-10-04 Vijayabhaskar Bolugoddu Preparation of ramipril and stable pharmaceutical compositions
WO2007120930A2 (en) * 2006-04-19 2007-10-25 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical compositions of 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivatives
EP2034966A1 (en) * 2006-06-30 2009-03-18 Alphapharm Pty Ltd. A stabilised composition comprising ace inhibitors
US20080071141A1 (en) * 2006-09-18 2008-03-20 Abhisuek Gattani Method and apparatus for measuring attributes of an anatomical feature during a medical procedure
US8337817B2 (en) 2006-12-26 2012-12-25 Shin Nippon Biomedical Laboratories, Ltd. Preparation for transnasal application
WO2008132756A1 (en) * 2007-05-01 2008-11-06 Lupin Limited Stable pharmaceutical compositions of ramipril
JP5113476B2 (ja) * 2007-10-09 2013-01-09 沢井製薬株式会社 保存安定性に優れた塩酸テモカプリルの錠剤
US9101539B2 (en) * 2009-05-15 2015-08-11 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
US8827946B2 (en) 2009-07-31 2014-09-09 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
TR200906322A2 (tr) 2009-08-17 2011-07-21 Bi̇lgi̇ç Mahmut Çözünürlük ve stabilite özellikleri geliştirilmiş granüller.
ES2364011B1 (es) 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
TN2010000566A1 (en) * 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
CN102512656B (zh) * 2011-12-27 2013-11-27 天津市嵩锐医药科技有限公司 盐酸喹那普利药物组合物
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320029A (en) * 1967-05-16 Method of preparing magnesia
IL58849A (en) * 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4344949A (en) * 1980-10-03 1982-08-17 Warner-Lambert Company Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
US4425355A (en) * 1981-02-17 1984-01-10 Warner-Lambert Company Substituted acyl derivatives of chair form of octahydro-1H-indole-2-carboxylic acids
US4830853A (en) * 1986-10-20 1989-05-16 Warner-Lambert Company Drug compositions stabilized against oxidation
US4793998A (en) * 1986-10-20 1988-12-27 Warner-Lambert Company Stabilized drug compositions
US4743450A (en) * 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
US4830583A (en) * 1988-03-02 1989-05-16 Sri International Fluid motor-pumping apparatus and system
US5622985A (en) * 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
HU222489B1 (hu) 1990-07-25 2003-07-28 Novartis Ag. Stabilizált gyógyszerkészítmények és eljárás az előállításukra
IT1251153B (it) * 1991-08-06 1995-05-04 Vectorpharma Int Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica
JP3414539B2 (ja) * 1994-05-11 2003-06-09 有限会社ドット 経鼻吸収用組成物
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
DE69925269T2 (de) * 1998-06-05 2006-02-23 Warner-Lambert Co. Llc Stabilisierung von zusammensetzungen enthaltend ace-hemmer durch magnesiumoxid
NZ333206A (en) * 1998-12-08 2000-07-28 Bernard Charles Sherman Solid pharmaceutical compositions comprising a stable magnesium salt of quinapril that acts as a ACE (Angiotensin Converting Enzyme) inhibitor

Also Published As

Publication number Publication date
EP1083931A1 (en) 2001-03-21
EP1083931B1 (en) 2005-05-11
AU755616B2 (en) 2002-12-19
UY25546A1 (es) 1999-09-27
HK1038879B (zh) 2004-10-08
PE20000543A1 (es) 2000-08-10
US7015232B2 (en) 2006-03-21
WO1999062560A1 (en) 1999-12-09
BR9910947A (pt) 2001-03-06
AU3979399A (en) 1999-12-20
AR019150A1 (es) 2001-12-26
IS2270B (is) 2007-07-15
US20020161020A1 (en) 2002-10-31
MY119667A (en) 2005-06-30
DE69925269T2 (de) 2006-02-23
HUP0102260A2 (hu) 2002-03-28
ZA200006537B (en) 2001-11-12
US20060106057A1 (en) 2006-05-18
JP2002516881A (ja) 2002-06-11
NO20006148L (no) 2000-12-04
CA2330581A1 (en) 1999-12-09
NZ508544A (en) 2002-10-25
ATE295184T1 (de) 2005-05-15
NO20006148D0 (no) 2000-12-04
SV1999000072A (es) 2000-05-04
KR20010052557A (ko) 2001-06-25
JP3727848B2 (ja) 2005-12-21
ID27398A (id) 2001-04-05
PA8475001A1 (es) 2000-09-29
TR200003600T2 (tr) 2001-04-20
GT199900079A (es) 2000-11-25
PL344586A1 (en) 2001-11-05
CN1144598C (zh) 2004-04-07
IL139590A0 (en) 2002-02-10
DE69925269D1 (de) 2005-06-16
CN1304322A (zh) 2001-07-18
ES2242398T3 (es) 2005-11-01
TW565455B (en) 2003-12-11
US6417196B1 (en) 2002-07-09
HK1038879A1 (en) 2002-04-04
CO5011043A1 (es) 2001-02-28
HN1999000088A (es) 2000-02-10
HUP0102260A3 (en) 2002-12-28

Similar Documents

Publication Publication Date Title
IS2270B (is) Faststilling lyfjablandna sem í eru angíótensínumbreytiensím með magnesíumoxíði
PT945132E (pt) Composicao de ibuprofeno
AU2001236497A1 (en) Anhydrous antiperspirant compositions containing water-reactive monomers as antiperspirant active
DE69904372D1 (de) Anschwellende feuerabdichtungszusammensetzung
IS2871B (is) Töflur sem innihalda 250 til 450 mg af módafíníli
AU5305899A (en) Powdery pernasal compositions
IL141157A0 (en) Salt form of pantoprazole and pharmaceutical compositions containing the same
AU6631200A (en) Low stress to seal gasket
ATE360374T1 (de) Feste zusammensetzungen zur verminderung der zahnerosion
PT1014987E (pt) Composicoes orais de levosimendano
ITMI982222A0 (it) Composizioni farmaceutiche orali contenenti buprenorfina
AU1769400A (en) Gas detection according to the principle of measuring work functions
AU2002247357A1 (en) Polybutene containing denture cleanser compositions
AU2003214887A1 (en) Compositions and methods for polynucleotide sequence determination
AU2001238718A1 (en) Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor
AU3191599A (en) Compositions containing lysophosphatidic acids which inhibit apoptosis and uses thereof
IS5958A (is) 3, 4, 5-þrístaðgengin arýlnítronefnasambönd og lyfjablöndur sem slík efnasambönd eru í
AU3066402A (en) Reduced byproduct high solids polyamine-epihalohydrin compositions
AU2003287063A1 (en) Hemostatic and acid etch compositions containing sucralose
AU2003217916A8 (en) Stable formulations of angiotensin converting enzyme (ace) inhibitors
NO20011664L (no) Sammensetning med höy renhet omfattende (7<alfa>, 17<alfa>)- 17-hydroksy-7-metyl-19-nor-17-pregn-5(10)-en-20-yn-3-on
AU2003241103A1 (en) Compositions containing anti-hiv peptides and methods of use
LU90483B1 (fr) Compositions nouvelles de m-thanesulfonate de parox-tine
ATE303153T1 (de) Ibandroinsäure zur förderung der osseointegration der endoprothesen
AU7065500A (en) Compounds useful to mimic peptide beta-strands